Human papillomavirus vaccine recombinant bivalent - Shanghai Zerun Biotechnology

Drug Profile

Human papillomavirus vaccine recombinant bivalent - Shanghai Zerun Biotechnology

Alternative Names: HPV-16/18 vaccine - Shanghai Zerun Biotechnology; HPV-2 vaccine - Shanghai Zerun Biotechnology; Human papillomavirus (types 16, 18) L1 virus-like particle vaccine - Shanghai Zerun Biotechnology; Recombinant human papillomavirus bivalent (types 16 and 18) vaccine - Shanghai Zerun Biotechnology

Latest Information Update: 19 Apr 2016

Price : $50

At a glance

  • Originator Shanghai Zerun Biotechnology Co
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Human papillomavirus infections

Most Recent Events

  • 01 Feb 2016 Phase-II clinical trials in Human papillomavirus infections (In adolescents, In children, Prevention, In volunteers) in China (IM) (NCT02740777)
  • 05 Mar 2012 Phase-I clinical trials in Human papillomavirus infections (In adolescents, In children, Prevention, In volunteers, In adults) in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top